公开(公告)号：US20170219591A1

公开(公告)日：2017-08-03

申请号：US15377091

申请日：2016-12-13

Applicant: CELERA CORPORATION

Inventor： Bruno DOMON ,  Ian MCCAFFREY ,  Vaibhav NARAYAN ,  Scott PATTERSON

IPC: G01N33/574 ,  C12Q1/68 ,  C07K14/745 ,  C07K14/705 ,  C07K14/71 ,  C07K14/81 ,  C12N9/10 ,  C12N9/14 ,  C07K14/47 ,  C12N9/02 ,  C07K16/40 ,  C07K16/28 ,  C07K16/38 ,  C07K16/36 ,  C12N15/113

CPC classification number: G01N33/57438 ,  C07K14/4705 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/70596 ,  C07K14/71 ,  C07K14/745 ,  C07K14/8114 ,  C07K16/18 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/38 ,  C07K16/40 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/622 ,  C12N9/001 ,  C12N9/1044 ,  C12N9/14 ,  C12N15/113 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Y103/01071 ,  C12Y203/02013 ,  C12Y306/03009 ,  G01N2500/00 ,  Y10T436/25

Abstract: The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAT) and antibodies binds to PCAT. The present invention provides that PCAT is used as targets for screening agents that modulates the PCAT activities. Further, the present invention provides methods for treating diseases associated with pancreas.

公开(公告)号：US09700027B2

公开(公告)日：2017-07-11

申请号：US15263916

申请日：2016-09-13

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Andrew J. Murphy ,  Cagan Gurer

IPC: C12N15/90 ,  A01K67/027 ,  C12N15/63 ,  C12N15/79 ,  A61K49/00 ,  C12N15/85 ,  C12N15/89 ,  G01N33/50 ,  C12N9/16 ,  C07K16/28 ,  C07K14/705

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0331 ,  A01K2267/0381 ,  A01K2267/0387 ,  A61K49/0008 ,  C07K14/70503 ,  C07K14/70596 ,  C07K16/2809 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2319/00 ,  C12N9/16 ,  C12N15/8509 ,  C12N15/89 ,  C12N15/902 ,  C12N15/907 ,  C12N2015/8518 ,  C12N2015/8527 ,  C12N2015/8572 ,  C12N2800/30 ,  C12Y301/03048 ,  G01N33/5011 ,  G01N33/5088 ,  G01N2500/04 ,  G01N2500/10

Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

公开(公告)号：US20170156389A1

公开(公告)日：2017-06-08

申请号：US15441405

申请日：2017-02-24

Applicant: N.V. Nutricia

Inventor： Thomas LUDWIG ,  Sylvie HUYBERS ,  Evan ABRAHAMSE ,  Houkje BOURITIUS

IPC: A23L33/00 ,  A61K31/7004 ,  A61K31/702 ,  A23L33/17 ,  A61K35/744 ,  A61K38/17 ,  A61K31/716 ,  A23L33/135 ,  A61K35/20 ,  A61K31/19

CPC classification number: A23L33/40 ,  A23L33/135 ,  A23L33/17 ,  A23V2002/00 ,  A23Y2220/17 ,  A23Y2220/39 ,  A23Y2220/49 ,  A23Y2220/63 ,  A23Y2220/67 ,  A23Y2220/73 ,  A23Y2220/77 ,  A23Y2220/79 ,  A23Y2240/00 ,  A23Y2240/75 ,  A61K31/19 ,  A61K31/7004 ,  A61K31/702 ,  A61K31/716 ,  A61K35/20 ,  A61K35/744 ,  A61K38/1709 ,  C07K14/70596 ,  C07K2319/95 ,  A23V2200/30 ,  A23V2200/32 ,  A23V2250/284 ,  A23V2250/54 ,  A23V2200/3202 ,  A23V2250/5424 ,  A23V2200/3204 ,  A23V2250/042

Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

公开(公告)号：US20170137785A1

公开(公告)日：2017-05-18

申请号：US15411125

申请日：2017-01-20

Applicant: Emory University ,  Georgia Tech Research Corporation

Inventor： Michael E. Davis ,  Archana V. Boopathy

IPC: C12N5/077 ,  C12N5/00

CPC classification number: C12N5/0657 ,  A61K35/34 ,  C07K14/00 ,  C07K14/70596 ,  C07K2319/70 ,  C07K2319/75 ,  C12N5/0068 ,  C12N2501/42 ,  C12N2533/50

Abstract: This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.

公开(公告)号：US09617327B2

公开(公告)日：2017-04-11

申请号：US14407907

申请日：2013-06-14

Applicant: N.V. Nutricia

Inventor： Thomas Ludwig ,  Sylvie Huybers ,  Evan Abrahamse ,  Houkje Bouritius

IPC: C07K14/705 ,  A61K31/702 ,  A61K35/744 ,  A23L33/00 ,  A23L33/135 ,  A23L33/17

CPC classification number: A23L33/40 ,  A23L33/135 ,  A23L33/17 ,  A23V2002/00 ,  A23Y2220/17 ,  A23Y2220/39 ,  A23Y2220/49 ,  A23Y2220/63 ,  A23Y2220/67 ,  A23Y2220/73 ,  A23Y2220/77 ,  A23Y2220/79 ,  A23Y2240/00 ,  A23Y2240/75 ,  A61K31/19 ,  A61K31/7004 ,  A61K31/702 ,  A61K31/716 ,  A61K35/20 ,  A61K35/744 ,  A61K38/1709 ,  C07K14/70596 ,  C07K2319/95 ,  A23V2200/30 ,  A23V2200/32 ,  A23V2250/284 ,  A23V2250/54 ,  A23V2200/3202 ,  A23V2250/5424 ,  A23V2200/3204 ,  A23V2250/042

Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.

公开(公告)号：US09605276B2

公开(公告)日：2017-03-28

申请号：US14422504

申请日：2013-03-15

Applicant: Frank R Jones ,  Elizabeth Gabitzsch

Inventor： Frank R Jones ,  Elizabeth Gabitzsch

IPC: A01N63/00 ,  C12N15/86 ,  C07K14/705 ,  A61K39/00 ,  C12N7/00

CPC classification number: C12N15/86 ,  A61K39/0011 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/545 ,  C07K14/4748 ,  C07K14/70503 ,  C07K14/70596 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2799/022

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US20170049852A1

公开(公告)日：2017-02-23

申请号：US15296218

申请日：2016-10-18

Applicant: Wisconsin Alumni Research Foundation

Inventor： Alan Rapraeger

IPC: A61K38/17

CPC classification number: A61K38/177 ,  C07K14/4703 ,  C07K14/70596 ,  C07K2319/23

Abstract: The invention provides for peptides from syndecan 1 and methods of use therefor. These peptides can inhibit α4β6 interaction with HER2, thereby preventing tumor cell growth and tissue invasion. The peptides can further be used to inhibit scarring and/or to inhibit pathologic neovascularization in a subject.

Abstract translation: 本发明提供了来自syndecan 1的肽及其用途的方法。 这些肽可以抑制α4β6与HER2的相互作用，从而防止肿瘤细胞生长和组织侵袭。 肽可进一步用于抑制受试者的瘢痕形成和/或抑制病理性新生血管形成。

公开(公告)号：US20170044256A1

公开(公告)日：2017-02-16

申请号：US15239569

申请日：2016-08-17

Applicant: Genentech, Inc.

Inventor： Jane GROGAN ,  Robert J. JOHNSTON ,  Bryan IRVING ,  Jason HACKNEY ,  Xin YU ,  Dan EATON ,  Kristin BOWLES ,  Laetitia COMPS-AGRAR

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06

CPC classification number: C07K16/2803 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0331 ,  A01K2267/0387 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K14/70596 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2319/30 ,  Y02A50/466

Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

Abstract translation: 本发明描述了包含PD-1轴结合拮抗剂和降低或抑制TIGIT表达和/或活性的试剂的组合治疗及其使用方法，包括治疗需要增强免疫原性的病症的方法，例如增加肿瘤免疫原性 治疗癌症或慢性感染。

公开(公告)号：US20170022506A1

公开(公告)日：2017-01-26

申请号：US15136653

申请日：2016-04-22

Applicant: Genzyme Corporation ,  Christian-Albrechts-Universitaet Zu Kiel

Inventor： David J. Reczek ,  Paul Saftig ,  Christine T. DeMaria

IPC: C12N15/113 ,  C07K16/40 ,  C07K16/28

CPC classification number: C12N15/1138 ,  C07K14/70596 ,  C07K16/2896 ,  C07K16/40 ,  C07K2317/76 ,  C12N9/2402 ,  C12N2310/14 ,  C12N2320/30 ,  C12P21/02 ,  C12Y302/01045

Abstract: The invention is directed to methods of producing a polypeptide or a variant thereof, wherein the polypeptide or variant thereof is dependent on LIMP-2 for trafficking, localization, stabilization and/or sorting of the polypeptide in the cell. In general, the methods comprise culturing a lysosomal integral membrane protein II (LIMP-2) deficient cell which expresses the polypeptide or the variant thereof under conditions in which the polypeptide or the variant thereof is produced.

Abstract translation: 本发明涉及产生多肽或其变体的方法，其中多肽或其变体依赖于LIMP-2用于细胞中多肽的运输，定位，稳定和/或分选。 通常，所述方法包括在产生多肽或其变体的条件下培养表达多肽或其变体的溶酶体整合膜蛋白II（LIMP-2）缺陷型细胞。

公开(公告)号：US20160376375A1

公开(公告)日：2016-12-29

申请号：US15038997

申请日：2014-11-21

Applicant: BAYLOR COLLEGE OF MEDICINE

Inventor： Gianpietro Dotti ,  Soldano Ferrone

IPC: C07K16/30 ,  A61K35/17 ,  C07K14/705

CPC classification number: C07K16/3076 ,  A61K35/17 ,  A61K2039/505 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/30 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/01 ,  C07K2319/03 ,  C07K2319/30

Abstract: Embodiments of the disclosure include methods and compositions related to chimeric antigen receptors (CAR) that target chondroitin sulfate proteoglycan-4 (CSPG4). T cells transduced with a CSPG4-specific CAR are effective for inhibition of particular cancer cells that express CSPG4. In certain embodiments, the cancer is melanoma, breast cancer, head and neck cancer, mesothelioma, glioblastoma, or renal cancer.

Abstract translation: 本公开的实施方案包括与靶向硫酸软骨素蛋白聚糖-4（CSPG4）的嵌合抗原受体（CAR）相关的方法和组合物。 用CSPG4特异性CAR转导的T细胞对表达CSPG4的特定癌细胞的抑制是有效的。 在某些实施方案中，癌症是黑素瘤，乳腺癌，头颈癌，间皮瘤，成胶质细胞瘤或肾癌。